A research collaboration has led to a new potential treatment for hereditary hemorrhagic telangiectasia (HHT) or Rendu-Osler syndrome, a rare disease that affects blood vessels and was previously untreatable. The study, published ...
Apr 27, 2018
0
1
A multi-institutional research team has identified what may be a novel mechanism underlying acquired resistance to CDK 4/6 inhibitor treatment for breast cancer. In their report published in the Annals of Oncology, the team—led ...
Apr 11, 2018
0
5
The structure of proteins that protect telomeres (shelterin proteins, from "protective shield") are promising targets to combat cancer, but to date, there has been no effective form for attacking them. In the absence of drugs ...
Nov 3, 2017
0
3
About one-third of patients with ovarian cancer who wouldn't be expected to respond to a PARP inhibitor had partial shrinkage of their tumor when a kinase inhibitor was added to treatment, report scientists from Dana-Farber ...
Apr 3, 2017
0
2
Breast cancer cells became resistant to therapeutics targeting CDK4/6, such as palbociclib (Ibrance), in multiple ways, and preclinical studies suggested different combinations of therapeutics may prevent and overcome the ...
Mar 28, 2016
0
6
A new oral targeted drug, idelalisib (GS-1101), has the potential to stave off the need for additional treatments for relapsed or treatment-resistant chronic lymphocytic leukemia (CLL), according to a study led in part by ...
May 17, 2013
0
0
Although a large majority of head and neck cancers have a deregulation of the PI3K/AKT/mTOR pathway, data recently published in Cancer Research, a journal of the American Association for Cancer Research, indicated that deregulation ...
Jan 29, 2013
0
0
Many different genetic alterations were detected in tumor cells left behind after patients with triple-negative breast cancer were treated with chemotherapy prior to surgery (neoadjuvant chemotherapy), according to data presented ...
Dec 7, 2012
0
0
Early changes in liver function detected by novel techniques can identify severe infection (sepsis) hours after onset and so could have important implications for the treatment of patients who are critically ill, according ...
Nov 13, 2012
0
0
(HealthDay)—Noncanonical Hedgehog (Hh) signaling is activated in tamoxifen-resistant tumors, and the phosphoinositide 3-kinase inhibitor/protein kinase B (PI3K/AKT) pathway plays a key role protecting Hh signaling molecules, ...
Nov 6, 2012
0
0
